1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. J Adv Res. 2020; 24: 91-98. [
DOI:10.1016/j.jare.2020.03.005] [
PMID] [
PMCID]
2. Stauffer WM, Alpern JD, Walker PF. COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyper infection. JAMA.2020;324(7):623-624. [
DOI:10.1001/jama.2020.13170] [
PMID]
3. Patel SK, Saikumar G, Rana J, DhamaJ, Yatoo MI, Tiwari R, et al. Dexamethasone: a boon for critically ill COVID-19 patients?. Travel Med Infect Dis. 2020;37:101844. [
DOI:10.1016/j.tmaid.2020.101844] [
PMID] [
PMCID]
4. Wilton AD, Nabarro LE, Godbole GS, Chiodini PL. Risk of Strongyloides Hyper infection Syndrome when prescribing dexamethasone in severe COVID-19. Travel Med Infect Dis. 2021; 40: 10198. [
DOI:10.1016/j.tmaid.2021.101981] [
PMID] [
PMCID]
5. VafaeEslahi A, Olfatifar M, Houshmand E, GhanbariJohkool M, Zibaei M, Foroutan M, et al. Prevalence of Strongyloides stercoralis in the immunocompetent and immunocompromised individuals in Iran: a systematic review and meta-analysis. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2021 Jul 23. [
DOI:10.1093/trstmh/trab104] [
PMID]
6. Kassalik M, Moenkemueller K. Strongyloides stercoralis hyper infection syndrome and disseminated disease. GastroenterolEpatol.2011; 7(11): 766-768.
7. KaranamL SK, Basavraj GK, Papireddy CKR. Strongyloides stercoralis Hyper infection Syndrome. Indian J Surg. 2020. [
DOI:10.1007/s12262-020-02292-x] [
PMID] [
PMCID]
8. Montes M, Sawhney C, Barros N. Strongyloides stercoralis: there but not seen. CurrOpin Infect Dis. 2010;23(5):500-4. [
DOI:10.1097/QCO.0b013e32833df718] [
PMID] [
PMCID]
9. Mejia R, Nutman TB. Screening, prevention, and treatment for hyper infection syndrome and disseminated infections caused by Strongyloides stercoralis. CurrOpin Infect Dis. 2012;25:458-63. [
DOI:10.1097/QCO.0b013e3283551dbd] [
PMID] [
PMCID]
10. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020. [
DOI:10.1038/s41392-020-0127-9] [
PMID] [
PMCID]
11. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther. 2020. [
DOI:10.1038/s41392-020-0158-2] [
PMID] [
PMCID]
12. Li R, Tian J, Yang F, Lv L, Yu J, Sun G, et al. Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan. China J Clin Virol. 2020; 127: 104363. [
DOI:10.1016/j.jcv.2020.104363] [
PMID] [
PMCID]
13. Marchese V, Crosato V, Gulletta M, Castelnuovo F, Cristini G, MatteelliA, et al. Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. Infection.2020; 10:1-4. [
DOI:10.1007/s15010-020-01522-4] [
PMID] [
PMCID]
14. Lier AJ, Tuan JJ, Davis MW, Paulson N, McManus D, Campbell S, et al. Case report: disseminated strongyloidiasis in a patient with COVID-19. Am J Trop Med Hyg. 2020;103(4):1590-1592. [
DOI:10.4269/ajtmh.20-0699] [
PMID] [
PMCID]